(Total Views: 636)
Posted On: 08/12/2020 5:47:52 PM
Post# of 155600
Interesting comment from SA aligned with your wildcard theory:
“Bridge to sell
Comments (2.52K)
Today, 5:25 PM
My concern is that the FDA will not grant EUA because they think the Phase 3 s/c will be successful and they do not want to deplete the limited available doses of Leronlimb on m/m patients. Even with a ramp up, it's likely that m/m cases would blow through the entire available supply before the Phase 3 s/c is fully analyzed.
Conversely, by applying for EUA in the UK, Mexico, and Israel the company has basically started the clock ticking to see who gets access to Leronlimab before it's all gone. It's a brilliant strategy that puts indirect pressure on the FDA...”
“Bridge to sell
Comments (2.52K)
Today, 5:25 PM
My concern is that the FDA will not grant EUA because they think the Phase 3 s/c will be successful and they do not want to deplete the limited available doses of Leronlimb on m/m patients. Even with a ramp up, it's likely that m/m cases would blow through the entire available supply before the Phase 3 s/c is fully analyzed.
Conversely, by applying for EUA in the UK, Mexico, and Israel the company has basically started the clock ticking to see who gets access to Leronlimab before it's all gone. It's a brilliant strategy that puts indirect pressure on the FDA...”
(3)
(1)
